Rational design of peptide-based tumor vaccines

Pharmaceutical Research

Volumn 19, Issue 7, 2002, Pages 926-932

  Meng, W S ^a   Butterfield, L H ^b  

^a DUQUESNE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antigenic peptides; Class I MHC; Cytotoxic T cells and tumor immunotherapy; Tumor associated antigens

Indexed keywords

EPITOPE; INTERLEUKIN 2; ISOLEUCYLMETHIONYLASPARTYLGLUTAMINYLVALYLPROLYLPHENYLALANYLSERYLVALINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; SUBUNIT VACCINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CLONAL VARIATION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG CONFORMATION; DRUG DESIGN; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR UPREGULATION; REVIEW; TUMOR IMMUNITY; VACCINE PRODUCTION; ANIMAL; CHEMISTRY;

ANIMAL; CANCER VACCINES; DRUG DESIGN; HUMAN; SUPPORT, NON-U.S. GOV'T; VACCINES, SUBUNIT; ANIMALS; HUMANS;

EID: 0035997324     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016497818471     Document Type: Review

References (66)

1. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
2. Strategies for immunotherapy of cancer
3. Progress in human tumour immunology and immunotherapy
4. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants
5. Inducing autoimmune disease to treat cancer
6. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2
7. An alpha-beta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex
8. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical
9. Peptide recognition by two HLA-A2/Tax11-19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures
10. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability
11. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes
12. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein
13. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
14. Consensus motifs and peptide ligands of MHC class I molecules
15. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
16. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
17. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
18. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
19. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
20. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response
21. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A 2.1 anchor residue
22. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
23. Status of activation of circulating vaccine-elicited CD8+ T cells
24. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
25. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
26. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
27. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection
28. Immune and clinical responses in patients with metastatic melanoma to CD34A+ progenitor-derived dendritic cell vaccine
29. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma
30. Effects of interleukin-12 on the immune response to a multipeptide vaccine for restricted metastatic melanoma
31. A superagonist varient of peptide MART/Melan A27-35 elicits antimelanoma CD8+ T cells with enhanced functional characteristics: Implication for more immunotherapy
32. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
33. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex
34. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
35. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human Carcinoembrionic antigen
36. Agonist peptide from cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of ts1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide
37. Assembly and transport of class I MHC-peptide complexes
38. Structure of the human class I histocompatibility antigen, HLA-A2
39. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules
40. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution
41. The antigenic identity of peptide-MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2
42. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity
43. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
44. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains
45. Both major and minor peptide-binding pockets in HLA-A2 influence the presentation of influenza virus matrix peptide to cytotoixc T lymphocytes
46. The structural basis for the increased immunogenicity of two HIV-reverse transcriptase peptide variant/class I major histocompatibility complexes
47. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: Implication in the identification of cryptic tumor epitopes
48. Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules
49. Altered peptide ligand design: Altering immune responses to class I MHC/peptide complexes
50. Crystal structure of an H-2K-b-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove
51. Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA-B53
52. Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts
53. The importance of pairwise interactions between peptide residues in the delineation of TCR specificity
54. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein
55. Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide
56. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes
57. A functional hot spot for antigen recognition in a superagonist TCR/MHC complex
58. MHC class I molecules, structure and function
59. High-resolution structure of HLA-A*0201 in complex with a tumor-specific antigenic peptide encoded by the MAGE-A4 gene
60. A model of water structure inside the HLA-A2 peptide binding groove
61. Water dynamics at the binding interface of four different HLA-A2-peptide complexes
62. Exploiting the peptide-MHC water interface in the computer-aided design of non-natural peptides that bind to the class I MHC molecule HLA-A2
63. Experimental evidence for the presence of a water network at the peptide-MHC interface
64. Substituting nonpeptidic spacers for the T cell receptor-binding part of class I major histocompatibility complex-binding peptides
65. Beta-amino acid scan of a class I major histocompatibility complex-restricted alloreactive T-cell epitope
66. Neural network method for predicting peptides that bind major histocompatibility complex molecules